Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Subscribe To Our Newsletter & Stay Updated